Related Experiment Video
Updated: Jun 9, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Correlation between expression of α₁-adrenoceptor subtype mRNA and severity of lower urinary tract symptoms or
Yoshiyuki Kojima1, Shoichi Sasaki, Makoto Imura
1Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. ykojima@med.nagoya-cu.ac.jp
Objective:
To examine whether the direct correlation between the expression of α₁-adrenoceptor (AR) subtype mRNA and severity of lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO) in the prostate exists in benign prostatic hyperplasia (BPH) patients.
Patients And Methods:
Sixty-eight patients with LUTS and BOO secondary to BPH were enrolled. Four prostate needle biopsy specimens were obtained from the transition zone to examine the expression level of α₁-AR subtypes by Taqman reverse-transcription polymerase chain reaction. The correlation and regression between each expression level of α₁-AR subtype and clinical findings such as patient age, prostate volume, International Prostate Symptom Score (IPSS), quality of life (QOL) index, maximum flow rate in uroflowmetry (Qmax) and post-void residual urine volume (PVR) were assessed by stepwise multiple regression analysis. The correlation and regression between this expression level and individual symptoms of IPSS were assessed by Pearson's correlation coefficient and multiple regression analyses.
Results:
Stepwise multiple regression analysis showed that the expression levels of α(1a) -AR, α(1b) -AR, α(1d) -AR and total α(1) -AR mRNA showed a significant regression with patient age, but not with prostate volume, IPSS, QOL index, Qmax and PVR. Pearson's correlation coefficient and multiple regression analyses demonstrated no correlation and regression between each α(1) -AR subtype mRNA expression level and individual symptoms of IPSS.
Conclusions:
There was no direct correlation between the expression of α₁-AR subtype mRNA in the prostate and severity of LUTS or BOO in BPH patients, although the significant regression of this expression with patient age existed. LUTS and BOO may be associated with multiple factors and several other conditions may contribute to LUTS and BOO.
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
